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OBJECTIVES: Modelling and forecasting the con-
sequences of AIDS on economic growth in Africa.
METHODS: Our model is based on two crucial hypoth-
esis: AIDS has a short-term impact on a ﬂow variable (the
ﬂow of labour available and capable of working at a
moment t in the economy); AIDS has a long-term impact
on stock variables (human capital, i.e. the stock of health
or the stock of education and competence incorporated
in the workers; and physical capital). The ﬁrst effect is
generally taken into account in the existing literature but
the second is missing. Data from Ivory Coast (data given
by UNAIDS and WHO) about macroeconomic variables
and epidemiologic situations are used to calibrate our
model. RESULTS: Integrating these two impacts in a
model of growth with multiple factors of accumulation is
sufﬁcient to reverse the standard impact-evaluations
based on classical tools. We show that, under a realistic
range of epidemiological shocks, an involution trap can
appear, corresponding to a modiﬁcation of the long-term
growth regime of the economy. CONCLUSIONS: When
the long term impact of AIDS is taken into account, the
impact of AIDS on economic growth in Africa is far worse
than predicted by UNAIDS for instance. In Ivory Coast,
the GDP loss is about 15% of the no-AIDS scenario in
2010 (against -8% for the UNAIDS forecast).
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OBJECTIVES: To investigate the potential role of phar-
macoeconomics in decision making and education.
METHODS: A group of 102 people with backgrounds in
health economics/pharmacoeconomics was interviewed.
Interviewees were students (23), medical doctors (28),
pharmacists (36), managers/economists (22) by educa-
tion, working in hospitals, outpatient clinics, pharmacies,
and the pharmaceutical industry. They were asked about:
sources of information that should be used by decision
makers at different levels of a Health care sector, barriers
to practical application of pharmacoeconomic evaluation
results, criteria for inclusion/exclusion of drugs in a hos-
pital formulary, means by which economic evaluation uti-
lization could become more common, needs for education
initiatives. RESULTS: A total of 86% of responders indi-
cated that expert opinion and 66% that articles in
reviewed scientiﬁc journals are the most important source
of information for reimbursement decisions. At manage-
ment level, also expert opinion (77%) and scientiﬁc jour-
nals (65%) played a key role. In relations between
pharmacist / physician and patient, personal opinion is
vital (58%), followed by experts’ opinion (55%) and
information from scientiﬁc press (50%). Limited interest
in pharmacoeconomic analyses focusing only on cost-
containment (77%) followed by lack of Governmental
Agencies’ involvement in introduction of regulations
(61%), difﬁculties in applying long-term view (57%) and
limited access to cost data (lack of national cost database)
(57%) were recognized as main barriers. On inclusion to
hospital formulary, acquisition cost (70%) and efﬁcacy
(96%) were crucial, hospital savings were less important
(50%). Wider use of pharmacoeconomic studies may be
due to more educational initiatives (74%), creation of
professional cost databases (72%) and transparent crite-
ria of evaluation (69%). A total of 86% of responders
declared the need to expand their knowledge. CON-
CLUSIONS: Education, cost databases and regulations
seem to be the most important in the future development
of pharmacoeconomics and health economics in Poland.
Conﬁrmation of these preliminary results requires
broader investigation.
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OBJECTIVES: To identify the main causes of variation in
study results from place to place, to assess whether the
variation differs by type of health economic study, to
assess whether differences among countries are systematic
and whether the differences are important for decision-
making. METHODS: A literature search was conducted
to identify economic evaluations of pharmaceuticals 
conducted in two or more European countries. These
included reports of multicountry studies and separate
reports of single country studies that were sufﬁciently
methodologically comparable. The studies identiﬁed were
then classiﬁed by methodological type and analysed to
assess their level of generalizability and to identify the
main causes of variation. Assessments were also made of
the extent to which differences in study results among
countries were systematic and whether they would lead
to a different decision, assuming a range of values of the
threshold willingness-to-pay for a life-year or quality-
adjusted life-year (QALY). RESULTS: In total 46 
intercountry drug comparisons were identiﬁed, 29 in mul-
ticountry studies and 17 in single country studies that
were considered to be sufﬁciently comparable in terms of
methodology. The type of study (i.e. trial-based or mod-
elling study) had some impact on generalizability, but a
more important factor was the extent of variation across
countries, in effectiveness, resource use or unit costs,
allowed by the researcher’s chosen methodology. Cost-
effectiveness results did differ widely between countries
